ONCS.Q Stock Overview OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. More details
Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
OncoSec Medical Incorporated Competitors Price History & Performance
Summary of share price highs, lows and changes for OncoSec Medical Historical stock prices Current Share Price US$0.13 52 Week High US$18.99 52 Week Low US$0.11 Beta 2 1 Month Change -68.98% 3 Month Change -94.83% 1 Year Change -99.25% 3 Year Change -99.70% 5 Year Change -99.95% Change since IPO -98.61%
Recent News & Updates OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer
OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement Jun 03 OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million. May 19
Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program May 17
High number of new directors Jan 04
OncoSec Medical Incorporated Receives Notice from the Nasdaq Stock Market LLC Dec 29 See more updates OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer
OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement Jun 03 OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million. May 19
Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program May 17
High number of new directors Jan 04
OncoSec Medical Incorporated Receives Notice from the Nasdaq Stock Market LLC Dec 29 OncoSec Medical Incorporated has completed a Follow-on Equity Offering. Dec 02
OncoSec Medical Incorporated has completed a Follow-on Equity Offering. Dec 01
OncoSec Medical Incorporated Presents Encouraging Early Data with TAVO™-EP combined with Nivolumab (Opdivo®) in Neoadjuvant Melanoma Nov 16
Oncosec Medical Incorporated Announces Positive Clinical Data of the Keynote-695 Trial Assessing Tavo-Ep in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to Anti-Pd-1 Treatment Nov 12
OncoSec Medical Incorporated Elects Robert H. Arch as Non-Independent Director of the Board Oct 18
OncoSec Medical Incorporated Elects Stephany Foster as an Independent Director Oct 12 OncoSec Medical Incorporated Announces Workforce Reduction
OncoSec to cut workforce by 45% as part of corporate restructuring Oct 04
OncoSec Medical Incorporated Appoints Joon Kim to the Audit Committee Jun 11
OncoSec Medical Incorporated, Annual General Meeting, Nov 23, 2022 Jun 10
OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement Jun 04 OncoSec Medical Incorporated Appoints Robert H. Arch as Chief Executive Officer
Price target decreased to US$5.00 Apr 27
Less than half of directors are independent Apr 27
OncoSec Medical Incorporated, Annual General Meeting, Jul 12, 2022 Apr 01
Price target decreased to US$5.00 Mar 17
OncoSec Medical Incorporated Announces Appointment of George Chi as Chief Financial Officer Feb 24
Oncosec Medical Receives Notice from the Nasdaq Stock Market Feb 17
Less than half of directors are independent Dec 15
Interim CEO & COO Brian Leuthner has left the company Aug 18
Forecast to breakeven in 2024 Aug 01
President, CEO & Director Daniel O'Connor has left the company Jun 29
OncoSec Medical Incorporated, Annual General Meeting, Apr 29, 2021 Mar 19
Price target raised to US$8.13 Mar 09
OncoSec Medical Incorporated Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, Tavo™, in Triple Negative Breast Cancer Mar 03
OncoSec Medical Incorporated Appoints Bridget O'keeffe as Vice President of Clinical Development Feb 19
OncoSec Medical Incorporated Announces Management Appointments Feb 03
New 90-day high: US$7.71 Jan 30
OncoSec Announces First Subjects Dosed in Phase 1 Trial of Corvax12, Oncosec's Covid-19 Vaccine Candidate Combining Interleukin-12 (Il-12) with an Enhanced Sars-Cov-2 Spike Protein Jan 28
What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry? Jan 28
OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $42.026498 million. Jan 22
OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™ Jan 20
New 90-day high: US$6.81 Jan 12
OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma Jan 09
Dosing underway in OncoSec's Tavo combo trial in skin cancer Jan 08
New 90-day high: US$6.65 Dec 17
OncoSec Medical Incorporated Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO and its Gene Electrotransfer Technology Dec 11
OncoSec Medical Incorporated Announces Exclusive License Agreement for Cliniporator Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics Nov 25
OncoSec: Undervalued And Continuing To Make Progress Nov 18
OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020 Nov 14
OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma Nov 09
New 90-day high: US$5.11 Nov 07
OncoSec Medical Incorporated to Present Positive Interim Data from Keynote-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma Nov 05
OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19 Oct 30
OncoSec Medical Incorporated Announces Stepping Down of Kellie Malloy Foerter as Chief Operating Officer Oct 14
OncoSec Medical Incorporated Announces Appointment of Sandra Aung as Senior Vice President, Chief Clinical Development Officer Oct 13
OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO and Its Gene Delivery Platform Oct 07
OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $14.977914 million. Aug 19 Shareholder Returns ONCS.Q US Biotechs US Market 7D -36.5% -2.4% -2.1% 1Y -99.3% -8.7% 21.3%
See full shareholder returns
Return vs Industry: ONCS.Q underperformed the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: ONCS.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility Is ONCS.Q's price volatile compared to industry and market? ONCS.Q volatility ONCS.Q Average Weekly Movement 28.4% Biotechs Industry Average Movement 11.2% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.2%
Stable Share Price: ONCS.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ONCS.Q's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company’s product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma.
Show more OncoSec Medical Incorporated Fundamentals Summary How do OncoSec Medical's earnings and revenue compare to its market cap? ONCS.Q fundamental statistics Market cap US$804.96k Earnings (TTM ) -US$29.39m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ONCS.Q income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$29.39m Earnings -US$29.39m
Last Reported Earnings
Jan 31, 2023
Earnings per share (EPS) -4.93 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -132.9%
How did ONCS.Q perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/06/28 18:20 End of Day Share Price 2023/06/28 00:00 Earnings 2023/01/31 Annual Earnings 2022/07/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources OncoSec Medical Incorporated is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Thomas Shrader BTIG Raghuram Selvaraju H.C. Wainwright & Co.
Show 8 more analysts 
